Pharmaceutical intermediates
Belumosudil mesylate Intermediates
4 pharmaceutical intermediates for Belumosudil mesylate. Indication: graft-versus-host disease.
About Belumosudil mesylate
- Originator
- Nabriva Therapeutics Plc; Kadmon Corporation Llc
- Indication
- graft-versus-host disease
- Approved Date
- 07/16/2021
- NCE Patent
- 07/16/2026
- DS/DP
- 10/30/2029
Available intermediates
4 intermediates currently listed for Belumosudil mesylate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-bromo-N-isopropylacetamide | 75726-96-4 | / | / |
| 1-BOC-5-AMINO-INDAZOLE | 129488-10-4 | / | / |
| Phenol, 3-(4-chloro-2-quinazolinyl)-, 1-acetate | 911417-24-8 | / | / |
| 5-AMINOINDAZOLE | 19335-11-6 | / | / |
Building toward Belumosudil mesylate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →